November 9-11, 2020
This year – wherever you’re located – you
can be part of the only online experience for
generics and biosimilars professionals
AN ONLINE EXPERIENCE FOR GENERIC AND BIOSIMILAR MEDICINES PROFESSIONALS
Biosimilars Review & Report is a proud sponsor of GRx+Biosims 2020!
Biosimilars Review & Report (BR&R) provides education, commentary, and updates on the U.S. biosimilar marketplace, a frequently updated resource covering the entire field, including: Biosimilar drug research and clinical trial development, blogs and posts with commentary, approvals, regulatory issues, contracting/rebating/pricing, biosimilar-related conference coverage, FDA advisory boards, and tracking of new market entrants.
is going virtual
The mission of providing America’s patients with access to the generic and biosimilar medicines they need remains our top priority. As this country faces the challenges of COVID-19, the importance of our mission comes into clearer focus – and the need to share knowledge and best practices has even greater urgency.
Due to public health and safety concerns related to the coronavirus (COVID-19) pandemic, we decided to web-stream the conference. The format may be new but will still allow you to participate in Q&A; with speakers, engage with your peers and meet with exhibitors.
Connecting to learn + share
solutions for the future
GRx+Biosims 2020 is the premier scientific and regulatory event for the U.S. generics and biosimilars industries, featuring timely programming relevant to technical, regulatory and policy professionals.
Top officials and subject-matter experts share their knowledge and best practices to enhance attendees’ understanding of how to succeed in generic and biosimilar development; the regulatory process and approvals: and the evolving policy landscape.